What is the ROCE (Return on Capital Employed) of FibroGen this year?
The ROCE of FibroGen is 1.32 undefined this year.
FibroGen ROCE 2024
FibroGen ROCE
1.32
Ticker
FGEN
ISIN
US31572Q8087
WKN
A12EZ0
In 2024, FibroGen's return on capital employed (ROCE) was 1.32, a -90.63% increase from the 14.07 ROCE in the previous year.
FibroGen Aktienanalyse
What does FibroGen do?
FibroGen Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company is headquartered in San Francisco, California, with offices in China and Europe. Since its founding in 1993, the company has undergone remarkable development. It was founded by three doctors, Dr. Thomas B. Neff, Dr. Michael W. Loberg, and Dr. Gerald L. McMahon, who specialized in fibrosis and gene therapy. From the beginning, the company focused on research on therapies for diseases caused by abnormal connective tissue or fibrosis. FibroGen's business model is based on the innovation of therapies for the treatment of various diseases. The company has developed unique solutions that can improve the quality of life for people with severe chronic illnesses. To expand its business, FibroGen is supported by renowned partners, including Astellas Pharma, AstraZeneca, and Roche. FibroGen now has three business areas: biopharmaceuticals, China, and partnerships. In the biopharmaceuticals field, the company focuses on the development of therapies for the treatment of anemia in chronic kidney disease and idiopathic pulmonary fibrosis. One candidate, Roxadustat, is already approved in China and Japan and is currently being studied in clinical trials in the United States and Europe. Another candidate, Pamrevlumab, is marketed for the treatment of idiopathic pulmonary fibrosis. The Chinese market is particularly important for FibroGen, as the company has been active there since the early 2000s and has a subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. FibroGen has also signed an agreement with AstraZeneca in China to jointly develop and market Roxadustat. FibroGen's partnership business focuses on developing targeted therapies for diseases in collaboration with other pharmaceutical companies. Genentech, a subsidiary of Roche, is one of FibroGen's largest partners. The two companies work together to develop therapies for the treatment of diabetic retinopathy. FibroGen has made significant progress in recent years and received many awards. For example, in 2020, the company received the Prix Galien USA in the category of "Best Biopharmaceutical," an award for innovative drugs in improving public health. In summary, FibroGen is an innovative biopharmaceutical company focused on the development and commercialization of therapies for life-threatening diseases. The company's business model is focused on collaborations with partners to develop targeted therapies. With its subsidiaries in China and Europe, FibroGen can offer therapeutic solutions worldwide. FibroGen ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling FibroGen's Return on Capital Employed (ROCE)
FibroGen's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing FibroGen's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
FibroGen's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in FibroGen’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about FibroGen stock
How has the ROCE (Return on Capital Employed) of FibroGen developed compared to the previous year?
The ROCE of FibroGen has increased by -90.63% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of FibroGen?
A high Return on Capital Employed (ROCE) indicates that FibroGen has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of FibroGen?
A low ROCE (Return on Capital Employed) can indicate that FibroGen has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from FibroGen impact the company?
An increase in the ROCE of FibroGen can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of FibroGen affect the company?
A decrease in ROCE of FibroGen can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of FibroGen?
Some factors that can affect FibroGen's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of FibroGen so important for investors?
The ROCE of FibroGen is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can FibroGen take to improve the ROCE?
To improve the ROCE, FibroGen can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does FibroGen pay?
Over the past 12 months, FibroGen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, FibroGen is expected to pay a dividend of 0 USD.
What is the dividend yield of FibroGen?
The current dividend yield of FibroGen is .
When does FibroGen pay dividends?
FibroGen pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of FibroGen?
FibroGen paid dividends every year for the past 0 years.
What is the dividend of FibroGen?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is FibroGen located?
FibroGen is assigned to the 'Health' sector.
Wann musste ich die Aktien von FibroGen kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of FibroGen from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.
When did FibroGen pay the last dividend?
The last dividend was paid out on 9/9/2024.
What was the dividend of FibroGen in the year 2023?
In the year 2023, FibroGen distributed 0 USD as dividends.
In which currency does FibroGen pay out the dividend?
The dividends of FibroGen are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The FibroGen stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von FibroGen
Our stock analysis for FibroGen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FibroGen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
